{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:40:29Z","timestamp":1790746829049,"version":"4.1.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Since the beginning of the COVID-19 pandemic, patients with Inborn Errors of Immunity have been infected by SARS-CoV-2 virus showing a spectrum of disease ranging from asymptomatic to severe COVID-19. A fair number of patients did not respond adequately to SARS-CoV-2 vaccinations, thus early therapeutic or prophylactic measures were needed to prevent severe or fatal course or COVID-19 and to reduce the burden of hospitalizations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Longitudinal, multicentric study on patients with Inborn Errors of Immunity immunized with mRNA vaccines treated with monoclonal antibodies and\/or antiviral agents at the first infection and at reinfection by SARS-CoV-2. Analyses of efficacy were performed according to the different circulating SARS-CoV-2 strains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis of the cohort of 192 SARS-CoV-2 infected patients, across 26 months, showed the efficacy of antivirals on the risk of hospitalization, while mabs offered a positive effect on hospitalization, and COVID-19 severity. This protection was consistent across the alpha, delta and early omicron waves, although the emergence of BA.2 reduced the effect of available mabs. Hospitalized patients treated with mabs and antivirals had a lower risk of ICU admission. We reported 16 re-infections with a length of SARS-CoV-2 positivity at second infection shorter among patients treated with mabs. Treatment with antivirals and mabs was safe.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The widespread use of specific therapy, vaccination and better access to care might have contributed to mitigate risk of mortality, hospital admission, and severe disease. However, the rapid spread of new viral strains underlines that mabs and antiviral beneficial effects should be re- evaluated over time.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.947174","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:20:24Z","timestamp":1659003624000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic"],"prefix":"10.3389","volume":"13","author":[{"given":"Giulia","family":"Garzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Firinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Lagnese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Punziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Laura","family":"Cinicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pulvirenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rattazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Milito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1","unstructured":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.37201\/req\/s01.14.2022","article-title":"Immune treatment in COVID-19","volume":"1","author":"Men\u00e9ndez","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1037","article-title":"Covid-19: What is the evidence for the antiviral paxlovid","volume":"377","author":"Extance","year":"2022","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542","article-title":"EPIC-HR investigators. oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2022.000008","article-title":"Two new oral antivirals for covid-19: molnupiravir and nirmatrelvir plus ritonavir","volume":"60","year":"2022","journal-title":"Drug Ther Bull"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: An international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1873767","article-title":"Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic","volume":"17","author":"Quinti","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.04.002","article-title":"Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity","author":"van Leeuwen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112915","article-title":"B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies","volume":"10","author":"Pulvirenti","year":"2021","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100470","article-title":"Monoclonal antibody therapy in kidney transplant recipients with delta and omicron variants of SARS-CoV-2: A single-center case series","volume":"100470","author":"Fernandes","year":"2022","journal-title":"Kidney Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0005732021","article-title":"SARS-CoV-2 neutralizing monoclonal antibodies for the treatment of COVID-19 in kidney transplant recipients","volume":"3","author":"Wang","year":"2021","journal-title":"Kidney360"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2974","article-title":"Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - a Czech multicenter experience","volume":"40","author":"Weinbergerov\u00e1","year":"2022","journal-title":"Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596761","article-title":"Case report: Convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19","volume":"11","author":"Van Damme","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835770","article-title":"Risk factors for severe COVID-19 and hospital admission in patients with inborn errors of immunity - results from a multicenter nationwide study","volume":"13","author":"Milota","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13223-021-00518-5","article-title":"Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma","volume":"17","author":"Ribeiro","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1038\/s41467-020-19761-2","article-title":"Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report","volume":"11","author":"Buckland","year":"2020","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.07.064","article-title":"Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia","volume":"110","author":"Palomba","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051026","article-title":"Mortality in severe antibody deficiencies patients during the first two years of the COVID-19 pandemic: Vaccination and monoclonal antibodies efficacy","volume":"10","author":"Milito","year":"2022","journal-title":"Biomedicines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab554","article-title":"Severe acute respiratory syndrome coronavirus 2 monoclonal antibody combination therapy in patients with coronavirus disease 2019 and primary antibody deficiency","volume":"225","author":"Pulvirenti","year":"2022","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B22","unstructured":""},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849","article-title":"BLAZE-1 investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108163","article-title":"Trial investigators. REGEN-COV antibody combination and outcomes in outpatients with covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934","article-title":"COMET-ICE investigators. early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100775","article-title":"When hematologic malignancies meet COVID-19 in the united states: Infections, death and disparities","volume":"47","author":"Wang","year":"2021","journal-title":"Blood Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"BLAZE-2 investigators. effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: A randomized clinical trial","volume":"326","author":"Cohen","year":"2021","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.15.21258542","article-title":"A randomized, controlled, open-label, platform trial","volume":"399","year":"2021","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033130","article-title":"A neutralizing monoclonal antibody for hospitalized patients with covid-19","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.868020","article-title":"Emulation of a target trial from observational data to compare effectiveness of Casirivimab\/Imdevimab and Bamlanivimab\/Etesevimab for early treatment of non-hospitalized patients with COVID-19","volume":"13","author":"Mazzotta","year":"2022","journal-title":"Front Immunol"},{"key":"B32","unstructured":"National Institutes of HealthCoronavirus disease 2019 (COVID-19) treatment guidelines"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"B34","article-title":"DETERMINA 4 agosto 2021, definizione delle modalita' e delle condizioni di impiego dell'anticorpo monoclonale sotrovimab, ai sensi del decreto 12 luglio","year":"2021"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103944","article-title":"Increased resistance of SARS-CoV-2 omicron variant to neutralization by vaccine-elicited and therapeutic antibodies","volume":"78","author":"Tada","year":"2022","journal-title":"EBioMedicine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac144","article-title":"Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation","volume":"10","author":"Padilla","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJMc2200591","article-title":"Outpatient remdesivir to prevent progression to severe covid-19. reply","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10875-022-01264-y","article-title":"The impact of SARS-CoV-2 infection in patients with inborn errors of immunity: the experience of the Italian primary immunodeficiencies network (IPINet)","volume":"20","author":"Giardino","year":"2022","journal-title":"J Clin Immunol"},{"key":"B40","unstructured":"indicazioni preliminari sulla somministrazione di dosi addizionali e di dosi \u201cbooster\u201d nell\u2019ambito della campagna di vaccinazione anti SARS-CoV-2\/COVID-192021"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2022.02.048","article-title":"Pediatric COVID-19 US registry. comorbidities associated with hospitalization and progression among adolescents with symptomatic coronavirus disease 2019","author":"Campbell","year":"2022","journal-title":"J Pediatr"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab-imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19","volume":"40","author":"Razonable","year":"2021","journal-title":"E Clin Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.031","article-title":"Impaired memory b-cell response to the pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency","volume":"149","author":"Fernandez Salinas","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-cilgavimab) for prevention of covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000789","article-title":"COVID-19 in complex common variable immunodeficiency patients affected by lung diseases","volume":"21","author":"Milito","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"B48","unstructured":""},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012251","article-title":"COVID-19 in patients with hematologic malignancy","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01133-0","article-title":"SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: Everybody does their best","volume":"41","author":"Salinas","year":"2021","journal-title":"J Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: The united kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1538","article-title":"Reinfection of severe acute respiratory syndrome coronavirus 2 in an immunocompromised patient: A case report","volume":"73","author":"Mulder","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1059","article-title":"Compassionate use of REGEN-COV \u00ae in patients with COVID-19 and immunodeficiency-associated antibody disorders","volume":"31","author":"Stein","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.888582","article-title":"Rare variants in inborn errors of immunity genes associated with covid-19 severity","volume":"12","author":"Liu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.655896","article-title":"IgA antibodies and IgA deficiency in SARS-CoV-2 infection","volume":"11","author":"Quinti","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202115326","article-title":"BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection","volume":"14","author":"Darwich","year":"2022","journal-title":"EMBO Mol Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00383-22","article-title":"Induction of broadly cross-reactive antibody responses to SARS-CoV-2 variants by S1 nanoparticle vaccines","author":"Sun","year":"2022","journal-title":"J Virol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10875-022-01283-9","article-title":"Neutralizing SARS-CoV-2 antibodies in commercial immunoglobulin products give patients with X-linked agammaglobulinemia limited passive immunity to the omicron variant","volume":"11","author":"Lindahl","year":"2022","journal-title":"J Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab331","article-title":"Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19","volume":"8","author":"Webb","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s15010-022-01825-8","article-title":"Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis","volume":"19","author":"Deng","year":"2022","journal-title":"Infection"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.947174\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:20:27Z","timestamp":1659003627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.947174\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2022.947174"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.947174","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"article-number":"947174"}}